Corcept Therapeutics | CORT - Debt


Corcept Therapeutics reported $6.36M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
ANI Pharmaceuticals USD 620.31M 1.25M Sep/2025
Ardelyx USD 207.61M 968K Sep/2025
Assertio Holdings USD 38.87M 615K Sep/2023
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Bristol-Myers Squibb USD 51.04B 112M Sep/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.36M 247K Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
J&J USD 45.8B 4.97B Sep/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
Lexicon Pharmaceuticals USD 99.26M 493K Sep/2023
Merck USD 41.37B 5.97B Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Omeros USD 442.16M 199K Sep/2023
Pacira USD 376.72M 203.77M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Supernus Pharmaceuticals USD 42.21M 10.44M Sep/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025